Publicacions en què col·labora amb Rocío Isabel Rodríguez Macías (65)

2024

  1. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology, Vol. 228

  2. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

  3. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

2022

  1. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  3. Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma

    HEPATOBILIARY SURGERY AND NUTRITION

  4. Liver and gastrointestinal cancers

    DRUG EFFLUX PUMPS IN CANCER RESISTANCE PATHWAYS: FROM MOLECULAR RECOGNITION AND CHARACTERIZATION TO POSSIBLE INHIBITION STRATEGIES IN CHEMOTHERAPY (ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD), pp. 197-250

  5. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  6. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

  7. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

  8. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1866, Núm. 5

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Chemoprotective Role of Vitamin C in Liver Diseases

    The Liver: Oxidative Stress and Dietary Antioxidants (Elsevier), pp. 139-153

  2. Chemoresistance and chemosensitization in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1444-1453

  3. Genetic heterogeneity of SLC22 family of transporters in drug disposition

    Journal of Personalized Medicine, Vol. 8, Núm. 2

  4. Molecular bases of the poor response of liver cancer to chemotherapy

    Clinics and Research in Hepatology and Gastroenterology

  5. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

    Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485

2017

  1. Molecular bases of chemoresistance in cholangiocarcinoma

    Current Drug Targets, Vol. 18, Núm. 8, pp. 889-900